Veru (VERU) stock Forecast for 2022 – 2026
Last update: 06-29-2022, 5:41Sector: Consumer defensive
The share price of Veru Inc. (VERU) now
What analysts predict:: $34
52-week high/low: $17.5 / $4.34
50/200 Day Moving Average: $12.17 / $8.15
This figure corresponds to the average price over the previous 50/200 days. For Veru stocks, the 50-day moving average is the resistance level today.
For Veru stocks, the 200-day moving average is the support level today.
Are you interested in Veru Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Veru stock price in 2022, 2023, 2024, 2025, 2026. How much will one Veru share be worth in 2022 - 2026?
When should I take profit in Veru stock? When should I record a loss on Veru stock? What are analysts' forecasts for Veru stock? What is the future of Veru stock?
We forecast Veru stock performance using neural networks based on historical data on Veru stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Veru stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Veru shares. This happens once a day.
Historical and forecast chart of Veru stock
The chart below shows the historical price of Veru stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Veru stock price can be found in the table below.
Long-term forecasts by years.
Veru daily forecast for a month
Veru Daily Price Targets
Veru Stock Forecast 07-01-2022.
Pessimistic target level: 11.71
Optimistic target level: 12.35
Veru Stock Forecast 07-02-2022.
Pessimistic target level: 11.48
Optimistic target level: 11.84
Veru Stock Forecast 07-03-2022.
Pessimistic target level: 10.65
Optimistic target level: 11.31
Veru Stock Forecast 07-04-2022.
Pessimistic target level: 10.46
Optimistic target level: 10.79
Veru Stock Forecast 07-05-2022.
Pessimistic target level: 10.17
Optimistic target level: 10.60
Veru Stock Forecast 07-06-2022.
Pessimistic target level: 10.53
Optimistic target level: 10.96
VERU (VERU) Monthly Stock Prediction for 2022
Veru forecast for this year
Veru Stock Prediction for Jul 2022
An uptrend is forecast for this month with an optimal target price of $12.6464. Pessimistic: $11.69. Optimistic: $13.66
Veru Stock Prediction for Aug 2022
An downtrend is forecast for this month with an optimal target price of $11.7358. Pessimistic: $10.94. Optimistic: $12.51
Veru Stock Prediction for Sep 2022
An uptrend is forecast for this month with an optimal target price of $12.3696. Pessimistic: $11.13. Optimistic: $14.10
Veru Stock Prediction for Oct 2022
An uptrend is forecast for this month with an optimal target price of $13.1612. Pessimistic: $12.56. Optimistic: $15.11
Veru Stock Prediction for Nov 2022
An downtrend is forecast for this month with an optimal target price of $13.1086. Pessimistic: $11.33. Optimistic: $13.92
Veru Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $15.4419. Pessimistic: $14.14. Optimistic: $17.88
Veru (VERU) Monthly Stock Prediction for 2023
Veru (VERU) Monthly Stock Prediction for 2024
Veru (VERU) Monthly Stock Prediction for 2025
Veru (VERU) Monthly Stock Prediction for 2026
Veru information and performance
Veru Inc. is an oncology and urology biopharmaceutical company specializing in the development of drugs for the treatment of prostate cancer. The company operates in two segments: Commercial and Research and Development. The commercial segment consists of FC2. The R&D segment consists of several drugs in clinical development for oncology and urology. The company’s prostate cancer pipeline includes VERU-111, VERU-100, and zuclomiphene citrate. VERU-111 is an oral chemical that targets, cross-links, and disrupts alpha and beta tubulin microtubule subunits. VERU-100 is a peptide formulation designed to address the limitations of commercially available treatments for androgen deprivation (ADT) in advanced prostate cancer. The company’s commercial products include the FC2 Female Condom/FC2 Internal Condom (FC2), a product to protect against unintended pregnancy and sexually transmitted infections.
515 NORTH STATE STREET, STE 2225, CHICAGO, IL, US
Market Capitalization: 1 084 198 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 1 104 700 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.023
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 117.65
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 16.21
Enterprise Value (EV) /Revenue
EV To EBITDA: 41.39
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 80074000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Veru (VERU) stock dividend
Veru last paid dividends on 04/28/2014. The next scheduled payment will be on 05/07/2014. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Factor:
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Consumer defensive sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.